quinazolines has been researched along with Epithelial Neoplasms in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 22 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Birrer, M; Buss, MK; Dahlberg, SE; Fleming, GF; Ivy, P; Lee, H; Liu, JF; Matulonis, UA; Tolaney, SM; Tyburski, K; Whalen, C; Winer, E | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Casado, A; Coens, C; Jimeno, A; Vergote, I | 1 |
| Freidlin, B; Korn, EL | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, H; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, S; Obermayer, L; Quy, P; Rimel, B; Whalen, C; Winer, EP | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA | 1 |
| Qiang, WA; Tan, W; Wang, SP; Wang, YT; Zhong, ZF | 1 |
| Clark, E; Cook, A; Eisenhauer, E; Embleton, AC; Farrelly, L; Friedlander, M; González-Martín, A; Hirte, H; Jayson, GC; Kaplan, RS; Kaye, SB; Ledermann, JA; Parmar, MKB; Perren, TJ; Raja, F; Rustin, GJS; Stark, D; Swart, AM; Vaughan, M | 1 |
| Angelo, LS; Gong, J; Kohanim, S; Kurzrock, R; Yang, DJ | 1 |
| Berkenblit, A; Berlin, S; Campos, S; Cannistra, SA; Hill, M; Horowitz, N; Humphreys, BD; Ivy, P; Krasner, C; Lee, H; Lee, J; Matulonis, UA; Penson, RT; Roche, M; Sullivan, L; Tran, C; Tyburski, K; Whalen, C; Zarwan, C | 1 |
| Dean, E; Hamilton, M; Judson, I; McCarthy, S; Ranson, M; Reid, A; Shaw, H; Wolf, J | 1 |
| Chang, HC; Connolly, K; DiGiovanni, J; Kiguchi, K; Kitamura, T; Moore, T; Ruffino, L; Rumi, M; Treece, D | 1 |
| Breinig, M; Chiosis, G; Dienemann, H; Giaccone, G; Goeppert, B; Harjung, A; Hartmann, A; Kern, MA; Malz, M; Mayer, P; Neumann, O; Penzel, R; Rieker, RJ; Schirmacher, P | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| Balko, JM; Black, EP; Britson, J; Bryant, JL; Frolov, A; Timmons, R; Willian, M | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Alberti, C; Canevari, S; Ditto, A; Ferri, R; Pinciroli, P; Sensi, M; Tomassetti, A; Umezawa, K; Valeri, B | 1 |
| Gui, T; Shen, K | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Harari, PM; Huang, SM | 1 |
| Blank, SV; Chang, R; Muggia, F | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ | 1 |
6 review(s) available for quinazolines and Epithelial Neoplasms
| Article | Year |
|---|---|
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult | 2015 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Humans; Neoplasms, Glandular and Epithelial; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2002 |
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
12 trial(s) available for quinazolines and Epithelial Neoplasms
| Article | Year |
|---|---|
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Carcinoma, Ovarian Epithelial; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Tablets; Treatment Outcome | 2013 |
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2014 |
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Quinazolines; Treatment Outcome | 2016 |
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines | 2010 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome | 2007 |
10 other study(ies) available for quinazolines and Epithelial Neoplasms
| Article | Year |
|---|---|
Reply to B. Freidlin et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Transparency in interim monitoring.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quinazolines | 2015 |
Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cysteine; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; Indium Radioisotopes; Mice; Mice, Nude; Molecular Imaging; Neoplasms, Glandular and Epithelial; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Technetium; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; Treatment Outcome | 2010 |
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
Topics: Aged; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Infant; Infant, Newborn; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Thymus Neoplasms | 2011 |
A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Quinazolines | 2012 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Topics: Benzamides; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Disease-Free Survival; ErbB Receptors; Female; Humans; Interleukin-6; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Plasminogen Activator Inhibitor 1; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Microenvironment; Tyrphostins | 2012 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |